EGFR-Mutant NSCLC

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial